Silence Therapeutics plc filings document a foreign biotechnology issuer whose American Depositary Shares trade on Nasdaq under SLN, with each ADS representing three ordinary shares. The record includes 8-K reports furnishing quarterly and annual financial results, business highlights, Regulation FD presentations and other events tied to siRNA pipeline development.
The company’s disclosures also cover proxy materials for shareholder voting and governance, board composition, executive departures and appointments, committee changes, and the relationship between listed ADSs and ordinary shares. Clinical and business exhibits describe programs from the mRNAi GOLD platform, including SANRECO updates for divesiran in polycythemia vera and collaboration-related disclosures involving AstraZeneca.
Silence Therapeutics plc reported a new stock option grant to director David Lemus. On January 2, 2026, he received a share option covering 90,000 ordinary shares with an exercise price of $2.05 per share and no cost for the grant itself. The option is scheduled to vest in equal monthly installments over one year, beginning one month after January 2, 2026, as long as he continues to serve the company on each vesting date. The option expires on January 2, 2036, and gives him the right to buy company shares in the future at the fixed exercise price.
Silence Therapeutics plc is undergoing significant leadership changes, as President, Chief Executive Officer and director Craig Tooman agreed by mutual consent to end his employment and step down from the Board effective December 14, 2025.
On the same date, Board Chairman Iain Ross was appointed as interim principal executive officer, with additional compensation terms still to be determined and to be covered in a later amendment. The Board also appointed James Ede-Golightly, age 46, to serve as a director with an initial term running until the Company’s 2026 annual general meeting, with his director compensation to be finalised later. The Company issued a December 15, 2025 press release about these changes, filed as Exhibit 99.1.
Silence Therapeutics plc reported third‑quarter results reflecting lower collaboration revenue and ongoing R&D investment. Revenue was $159 thousand in Q3 2025 versus $1.498 million a year ago, mainly due to fewer recognized AstraZeneca milestones. Net loss was $20.958 million (vs. $35.544 million), with operating expenses of $20.544 million in R&D and $5.795 million in G&A.
For the first nine months, revenue was $525 thousand (vs. $17.953 million) and net loss was $76.842 million (vs. $57.611 million). Cash, cash equivalents and short‑term investments totaled $102.2 million as of September 30, 2025, and management believes existing liquidity and anticipated collaboration milestones can fund operations into 2028. Contract liabilities tied to the AstraZeneca collaboration were $55.552 million, to be recognized over future periods.
Pipeline updates note divesiran (SLN124) Phase 2 SANRECO enrollment completed in October 2025, with initial topline results anticipated in the third quarter of 2026. Zerlasiran (SLN360) completed Phase 3 readiness activities, with partnering sought for Phase 3 and potential commercialization. Shares outstanding were 141,701,848 as of October 30, 2025.
Silence Therapeutics plc furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025, along with recent business highlights. The press release is provided as Exhibit 99.1 and is incorporated by reference. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.
The company’s American Depositary Shares trade on Nasdaq under SLN, with each ADS representing 3 ordinary shares of nominal value £0.05 per share.
Silence Therapeutics plc reported a clinical milestone under Other Events: it has completed enrollment in the SANRECO Phase 2 study of divesiran for treating polycythemia vera (PV).
The company furnished a press release as Exhibit 99.1. The information, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.
Silence Therapeutics plc reported that Michael Davidson resigned from its board of directors on August 11, 2025, stepping down immediately from the Board and from the Audit and Risk, Remuneration, and Science & Technology Committees. The company states that he left to focus on other time commitments, including his role as Chief Executive Officer of NewAmsterdam Pharma Company N.V., and that his resignation was not due to any disagreement with the company, its management, or the Board.
After his departure, the Board reduced its size from five to four directors. The Board also appointed its chairman, Iain Ross, to the Audit and Risk Committee to fill the vacancy created by Dr. Davidson’s resignation, maintaining coverage of this key governance function.
Silence Therapeutics plc (SLN) – Form 4 insider activity: Director and 10% owner Richard Ian Griffiths, through Cream Capital Ltd., reported two open-market purchases of American Depositary Shares (ADS).
- 31 Jul 2025: 14,342 ADS at $6.18
- 1 Aug 2025: 4,034 ADS at $6.14
The combined 18,376 ADS cost roughly $113 k and lifted his indirect holding to 11,825,861 ADS. Each ADS converts into three ordinary shares and has no expiration date. Griffiths disclaims beneficial ownership beyond his pecuniary interest.
The transactions modestly increase an already large position (<0.02 % incremental) and do not affect control status, but fresh insider buying can be viewed as a mild vote of confidence. No sales, options, or other derivative moves were disclosed.